AI-Based Diagnostic Systems for Lung Cancer: Innovations, Challenges, and Future Perspectives

Shantanu Sarnaik[1], Vishwajit Mane[2], Ziya Balbudhe[3], Mukesh Hiwarkar[4], Prof. Leelkanth Dewangan[5]
[1,2,3,4,5]*G H Raisoni College of Engineering, Nagpur*

***Abstract*—Lung cancer remains one of the leading causes of cancer-related deaths worldwide, with patient prognosis heavily reliant on timely diagnosis. Recent advancements in artificial intelligence (AI), particularly through deep learning and machine learning (ML) approaches, have significantly transformed diagnostic imaging and early detection strategies. This review consolidates studies utilizing AI-driven methods ranging from classical ML algorithms including traditional machine learning models, for example, support vector machines and artificial neural networks, as well as modern deep learning architectures such as convolutional neural networks, applied for the detection, segmentation, and classification of pulmonary nodules.**

A fully automated AI platform employing [18F] fluorodeoxyglucose (FDG) PET-CT imaging has demonstrated high sensitivity (90%) in detecting abnormal lung lesions and precisely estimating total lesion glycolysis (TLG), showing strong concordance with manual evaluations [23]. Systematic analyses of 39 studies further highlight AI's clinical utility, with pooled diagnostic sensitivity and specificity approaching 87% [14]. Deep learning models, particularly CNNs, have surpassed conventional CAD systems in distinguishing benign from malignant lung tissue, facilitating early intervention and enhancing patient outcomes [15], [16].

Although challenges remain, including model validation and standardization, AI-based diagnostic platforms provide a transformative avenue for lung cancer detection improving diagnostic precision, streamlining clinical workflows, and supporting personalized patient management.

***Index Terms*—AI, Lung Cancer, FDG PET-CT, Deep Learning, CNN, Diagnostic Imaging, Pulmonary Nodule, Total Lesion Glycolysis, Machine Learning, Early Detection**

I. INTRODUCTION

Lung cancer remains a major global health concern, responsible for a substantial percentage of cancer deaths. According to WHO and GLOBOCAN statistics, it causes nearly two million new cases each year, accounting for about 13

Unlike several cancers that can be discovered early via routine check-ups or self-assessment, lung cancer generally remains silent in its early phases, causing delays in diagnosis and therapy. When symptoms finally emerge, the condition is often at an advanced stage, limiting treatment possibilities and severely affecting survival chances [25].

The elevated death rate linked to lung cancer highlights the critical need for early diagnosis. Conventional diagnostic approaches such as chest radiography, computed tomography (CT), and magnetic resonance imaging (MRI) have notable shortcomings. These procedures depend greatly on the manual assessment by radiologists, making them time-demanding, resource-heavy, and susceptible to variations among observers. Furthermore, traditional imaging methods often lack the precision needed to accurately evaluate tumor behavior or guide individualized treatment plans.

In recent years, the swift progress of artificial intelligence

(AI) and machine learning (ML) has introduced promising advancements in the field of cancer research and diagnostics. These computational tools have shown outstanding capabilities in enhancing diagnostic accuracy, boosting workflow efficiency, and aiding medical decision-making. Among them, convolutional neural networks (CNNs) have achieved cutting-edge performance in image analysis tasks such as classification, segmentation, and detection of pulmonary nodules.

In addition, other ML models like support vector machines (SVMs), artificial neural networks (ANNs), k-nearest neighbor (kNN) algorithms, and fuzzy logic-based systems have been utilized for analyzing diverse

multimodal data. Modern computer-aided diagnosis (CAD) frameworks that combine PET-CT imaging with AI-driven algorithms are now capable of quantifying biomarkers such as total lesion glycolysis (TLG), a key predictive factor in non-small cell lung cancer (NSCLC).

Although substantial progress has been achieved, issues such as data variability, limited labeled datasets, and lack of algorithm interpretability continue to present barriers. Even so, the integration of AI technology into clinical diagnostic systems holds tremendous potential to enhance patient survival and treatment outcomes in lung cancer care.

II. LITERATURE REVIEW

The incorporation of artificial intelligence (AI) into medical diagnostics and imaging has advanced remarkably over the last twenty years, steering the development of computer-assisted diagnostic (CAD) frameworks across various medical fields. Earlier CAD techniques for lung cancer depended primarily on manually designed filters including Gaussian and median filters along with human-guided segmentation and feature derivation to detect potential nodules in CT images. While these approaches provided a starting point, they were limited by sensitivity to imaging protocols, restricted generalizability, and heavy dependence on expert-driven design.

The application of artificial intelligence (AI) in diagnostic imaging has progressed greatly over the last two decades, influencing the evolution of computer-aided detection (CAD) technologies across diverse medical areas. In its early stages, CAD approaches for lung cancer largely depended on manually designed filters such as median and Gaussian filters combined with manual feature extraction and segmentation techniques to detect abnormal nodules in CT scans. Several studies reported strong sensitivity and specificity, yet scalability remained constrained due to reliance on engineered features. This dependence often introduced human bias, preventing models from fully exploiting complex imaging patterns.

The emergence of deep learning (DL) transformed this landscape by eliminating the need for manual feature engineering. Deep learning models based on Convolutional Neural Networks (CNNs) notably VGG-16, ResNet-50, and DenseNet have demonstrated exceptional performance, attaining over 99

Although lung cancer has been a focal point of AI in imaging, similar trajectories have been observed in other disease domains. For example, in cardiology, machine learning models have been widely utilized for heart failure prediction, cardiovascular disease classification, and mortality risk assessment. Algorithms such as Random Forests, SVMs, and k-Nearest Neighbors (kNN) have demonstrated high performance, with some studies reporting predictive accuracies above 90%. Hybrid deep learning methods such as Convolutional Bi-directional LSTM (C-Bi-LSTM) have further improved cardiovascular risk prediction, achieving accuracies exceeding 94% on benchmark datasets. These advancements demonstrate how AI models are capable of capturing nonlinear clinical features that may elude traditional statistical approaches.

Similarly, in nephrology, predictive modeling of chronic kidney disease (CKD) has benefitted from ML techniques. Clustering methods like k-modes, along with classifiers such as Decision Trees and Logistic Regression, have successfully stratified patient risk using datasets such as the UCI CKD repository. Ensemble methods and hybrid models combining Random Forests with other classifiers have reached prediction accuracies close to 99%, highlighting the potential of AI to guide early diagnosis and intervention.

In diabetes care, predictive analytics and complication forecasting models have been developed using logistic regression, ANN, and hybrid learning approaches. These models not only support clinical diagnosis but also provide community level screening tools. Their success underscores the broader adaptability of AI to different disease domains, paving the way for comprehensive decision-support systems in preventive medicine.

AI has also shown promising results in brain tumor detection using MRI. Techniques such as Curvelet transforms for feature extraction, combined with Adaptive Neuro-Fuzzy Inference Systems (ANFIS) and Random Forest classifiers, have reported accuracies up to 98.5% in distinguishing normal from abnormal scans. These successes illustrate the versatility of AI across diverse imaging modalities, further reinforcing its value in precision diagnostics.

Despite these achievements, several challenges remain common across disease domains. First, the lack of large, standardized, annotated datasets continue to hinder generalizability. Models often suffer performance drops when applied to data from new scanners or institutions. Second, interpretability remains a concern, particularly in deep learning models, where the decision-making process can be opaque. This has fueled interest in explainable AI (XAI) to enhance trust and clinical adoption [19], [27]. Third, seamless integration into clinical workflows and compliance with regulatory frameworks (FDA, CE-marking) pose logistical and ethical hurdles. Privacy, fairness, and security including the use of multifactor authentication, encryption, and anonymization for patient records are essential for real-world deployment. The literature thus reflects a broader trajectory: from handcrafted feature engineering to deep learning driven precision systems, and from isolated disease-specific models to generalizable, explainable AI frameworks across healthcare. In lung cancer, the integration of AI with FDG PET-CT imaging exemplifies this progress by enabling accurate lesion detection, biomarker quantification, and prognostic modeling. The direction forward lies in creating robust, interpretable, and workflow-aware AI systems that augment clinicians as trusted second readers, improving efficiency and ultimately enhancing patient outcomes.

III. METHODOLOGY

A. Study Design and Patient Cohort

This retrospective study developed and validated an AIpowered diagnostic framework for lung lesion detection and segmentation using PET-CT imaging.In total 112 patients (59 females, 53 males, with an average age of 65.3±9.8 years) who underwent clinically indicated FDG PET-CT for suspected or confirmed lung cancer between April 2008 and December 2010 were considered for inclusion. Exclusion criteria comprised centrally located tumors, suspected sarcoidosis, or mediastinal tumors. Dataset partitions were as follows:

- Training set: 66 patients (59%)
- Validation set: 23 patients (20.5%)
- Test set: 23 patients (20.5%)

(maximum 400 MBq), followed by a 60-minute uptake period. Image acquisition was expanded to cover the area from the base of the skull to the mid-thigh. The CT scanning procedure employed a low-dose 64-slice helical technique, operating at 120 kV and 30 mAs. Using a 512×512 matrix, images were reconstructed with a 3 mm slice thickness and 1.37 mm pixel spacing, utilizing filtered back projection. The PET acquisition was performed at a rate of 3 minutes per bed position. Image reconstruction was performed using ordered subset expectation maximization (OSEM) with 4 iterations and 8 subsets [20]. The resulting images featured a matrix size of 168×168 and slice thickness of 3 mm.

B. Network Architecture

This AI model is constructed on a dual-CNN framework, comprising a pair of convolutional neural networks:

1) Organ Segmentation CNN: A pre-trained model adapted from prior work segments major anatomical structures including the lungs, vertebral bones, liver, heart, and aorta. The generated organ mask serves as an additional input to assist in detecting lesions.



Fig. 1. The schematic representation of the fundamental CAD system workflow.

2) Lesion Detection CNN: A customized CNN trained on PET-CT images for automatic identification and segmentation of pulmonary nodules.

C. Lesion Detection CNN

This network processes a three-channel input comprising coregistered CT, PET, and organ mask volumes. The architecture supports multiresolution feature extraction via pooling layers, enabling a large receptive field with efficient memory use. All convolutional layers employ ReLU activation, whereas the output layer uses softmax to generate voxel-level probability maps for lesions. Prior to input into the model, PET volumes are resampled to align with the spatial resolution of CT images.

A total of 66 volumes, containing 74 manually labeled lesions, were used to train the Detection CNN. Hyperparameter tuning was conducted on the validation set (23 volumes, 35 lesions).

Loss: Weighted negative log-likelihood with a 10 mm margin around annotations marked as "don't-care" and excluded from loss. Optimizer: Adam with Nesterov momentum; initial learning rate 1×10^{-4}, reduced on plateau of validation loss [21]. Training scheme: Each epoch comprised 500 batches, with 75 patches per batch. Patch size: 136×136×72 voxels. Hard negative mining: 10% of training samples oversampled from false-positive regions, repeated for 10 retraining cycles. Algorithm: Training with Hard Negative Mining

1) Initialize θ; set η =10^{-4}. 2) For cycle =1→10:

a) For epoch =1→ E:

i) For batch =1→500:

A) Sample patches (75 / batch) with PET, CT, organ masks.

B) Compute weighted NLL loss ignoring 10 mm margins.

C) Update $\theta \leftarrow \theta - \eta\nabla_\theta L$. ii) Reduce η on validation plateau.

b) Identify false positives (FPs) on validation; over-sample 10% FP regions next cycle.

D. Postprocessing

1) Region restriction: Processing confined to lung boundaries from the Organ CNN.
2) Noise reduction: Remove connected components with volume < 1 mL.
3) Blacklist masking: Exclude non-lung organs; dilate heart by 10 mm to eliminate adjacent high-uptake FPs.
4) SUVmax-guided refinement: Apply watershed on PET to assign voxels to local SUVmax; exclude voxels linked to blacklisted regions.

E. Ground Truth and Evaluation

Manual annotations were performed in RECOMIA on fused PET-CT images. Reader A (nuclear medicine specialist) performed primary annotations; a radiology resident verified. Readers B & C independently annotated the test set for interreader comparison [18].

Evaluation metrics included:

- Lesion-level sensitivity
- Dice Similarity Coefficient (DSC)
- Total Lesion Glycolysis (TLG): TLG = MTV × SUV_{mean}
- Agreement: Pearson correlation and Bland–Altman analysis between AI- and manual-derived TLG [18], [23]

IV. COMPREHENSIVE REVIEW AND QUANTITATIVE SYNTHESIS

In accordance with the PRISMA 2020 standards [14], PubMed, Scopus, Web of Science, Cochrane, and Google Scholar (up to October 2023) were searched using MeSH terms and keywords: "lung cancer", "pulmonary nodules", "AI", "machine learning", "diagnostic imaging", and "neural networks".

Inclusion criteria: Peer-reviewed English studies applying AI/ML on imaging datasets with reported diagnostic performance metrics. Exclusion criteria: non-imaging studies, phantom-only studies, non-ML techniques, editorials, and reviews.

From 5,894 records, 517 duplicates were removed.Out of 315 full-text articles reviewed, 9 studies satisfied the inclusion requirements. Methodological quality was assessed using the NHLBI tool (Fair: 0–4, Good: 5–9, Excellent: ≥ 10). Meta-analysis was performed using the meta and metafor packages in R 4.3.0, computing pooled sensitivity and specificity along with 95

TABLE I
Cohort and Data Split Summary

Split	Patients	Female/Male	Notes
Training	66	59/53 overall	74 lesions annotated
Validation	23	–	Hyperparameter tuning
Test	23	–	Inter-reader analysis

TABLE II
Example Performance Metrics (replace with actual results)

Metric	Value	95% CI
Sensitivity (lesion)	0.90	[0.82, 0.95]
DSC (segmentation)	0.82	[0.78, 0.86]
TLG Pearson r	0.96	[0.93, 0.98]

V. LUNG DIGITAL TWIN (LUNG-DT) PLATFORM

A modular microservices architecture supports real-time diagnosis and predictive modeling.

Acquisition: Connectors are provided for wearable SpO_2 monitors and chest X-ray uploads (secure transfer). Preprocessing steps include image resizing, intensity normalization, and metadata cleaning. All processed data are stored in a centralized repository.

AI Services: An orchestration agent manages inference using a YOLOv8-based CNN (anchor-free head, PPM backbone, CSPHead neck; optimized with AdamW) [22]. The model was trained on more than 23,000 chest X-rays across five diagnostic categories: normal, COVID-19, pneumonia, lung opacity, and tuberculosis.

Policy & Actions: Threshold-based predictions trigger automated alerts, clinical workflows, and emergency responses. The Lung-DT platform also enables integration with HeartDT, advancing toward a broader multi-organ Healthcare DT ecosystem.

Infrastructure: The architecture is containerized using Docker and orchestrated by Kubernetes, providing scalability, fault tolerance, and secure deployment in clinical settings.

VI. PROPOSED SOLUTION

The proposed AI-based PET-CT diagnostic framework is designed to integrate lesion detection, segmentation, classification, and biomarker quantification into a unified clinical workflow. By combining multi-modal imaging (CT, PET, and organ masks) with deep learning models, the system achieves robust lesion sensitivity and reproducibility of Total Lesion Glycolysis (TLG). The following figures present experimental results across multiple evaluation aspects: per-class metrics, threshold optimization, and overall discriminative performance. Figure 2 depicts the Receiver Operating Characteristic (ROC) curve for the proposed model. The model achieved an Area Under the Curve (AUC) of 0.61, indicating a moderate discriminative ability. Positioned above the random classifier line (shown as a dashed red line), the curve highlights the tradeoff between sensitivity (true positive rate) and specificity (false positive rate). This suggests that while the model can identify malignant cases better than chance, further optimization is needed to improve overall classification reliability.



Fig. 2. The ROC curve depicts the balance between sensitivity and specificity. The proposed model attained an AUC value of 0.61, reflecting a moderate level of discriminatory effectiveness.

The Precision–Recall (PR) curve demonstrates the relationship between precision and recall at different threshold values. For the proposed diagnostic framework, the curve highlights that recall remains consistently higher than precision, indicating the system's focus on minimizing false negatives. This is a clinically favorable property, as it ensures that malignant cases are rarely missed, although it comes at the cost of reduced precision due to increased false positives. The steep decline in precision with increasing recall suggests that while the model aggressively identifies potential malignancies, it struggles to maintain specificity. Such a trade-off is acceptable in oncological screening, where the priority lies in sensitivity to avoid missed detections. The overall low precision underscores the need for additional post-processing or ensemble strategies to reduce false alarms. Nevertheless, the elevated recall performance indicates the model's strong capability to identify clinically significant cancer cases.



Fig. 3. Precision–Recall (PR) curve showing the relationship between recall and precision. The curve demonstrates that the proposed model prioritizes sensitivity (recall) to ensure early cancer detection, even with reduced precision.

The F1-score versus threshold curve depicts the variation of the harmonic mean between precision and recall across multiple classification thresholds. The curve shows that the optimal threshold is around 0.95, where the F1-score peaks at approximately 0.25. This indicates that while overall precision is relatively low, the system achieves its best balance between precision and recall at this threshold. The steep decline in F1-score beyond 0.95 highlights the sensitivity of the model to threshold selection. Clinically, selecting such a threshold is important for ensuring that the model maintains high recall while still optimizing precision to some extent.



Fig. 4. F1-score vs. threshold curve showing the optimal balance point at a threshold of 0.95, where the F1-score reaches its maximum value.

The Balanced Accuracy vs. Threshold curve shows how the classification threshold influences the trade-off between sensitivity and specificity. The curve gradually increases, reaching its optimal performance around a threshold of 0.95, where the balanced accuracy peaks at approximately 0.61. This indicates that the system achieves the best balance between true positive rate and true negative rate near this threshold. Beyond 0.95, accuracy sharply declines, emphasizing the sensitivity of the model to threshold selection. Clinically, identifying this operating point ensures reliable cancer detection while maintaining reasonable specificity.



Fig. 5. Balanced Accuracy vs. Threshold curve. The curve shows that the optimal threshold is at 0.95, where balanced accuracy peaks at approximately 0.61, representing the best the relationship between sensitivity and specificity.

VII. DISCUSSION

Our framework demonstrates that multi-channel PET-CT inputs combined with organ priors can significantly enhance lesion sensitivity and yield accurate TLG quantification. The use of SUVmax-guided watershed segmentation alongside blacklist masking effectively reduces false positives near high-uptake



Fig. 6. CNN-based Lung Cancer Detection Workflow

non-lung organs, such as the liver and heart. Agreement with manual TLG measurements suggests that this approach is suitable for prognostic workflows and for prioritization of cases in a clinical setting [23]. Future directions include integration with electronic health record (EHR) data to support multimodal prognostic modeling. Additionally, the development of robust uncertainty quantification and out-of-distribution detection frameworks is needed. Federated learning is expected to significantly facilitate privacy preserving, multi-site model training while reducing the risk of data leakage [26].

In summary, the framework improves lesion sensitivity, reduces false positives, and shows potential for clinical deployment. Future directions include EHR integration, uncertainty quantification, and federated learning.

VIII. ETHICS & REGULATORY CONSIDERATIONS

All patient data used in this study were de-identified and processed in accordance with institutional review board policies. Any deployment of the proposed system must comply with regional regulations and consider pathways for regulatory approval, such as FDA Software-as-a-Medical-Device (SaMD) clearance or EU MDR certification. Furthermore, fairness audits are necessary to ensure that demographic or scanner-related biases do not affect clinical outcomes.

A. Clinical Implications

Automated TLG quantification expedites tumor burden assessment, enabling same-day multidisciplinary decisions and improving triage efficiency. By alleviating the workload of radiologists, the system can support more rapid decisionmaking in oncology processes, especially for non-small cell lung cancer patients, where prompt initiation of treatment is essential. Systematic reviews report pooled sensitivity and specificity values near 87%, which aligns with the performance envelope of our approach [14]. CNN-based systems consistently outperform traditional CAD techniques in classification and segmentation, highlighting the utility of deep learning for highdimensional PET-CT data [15], [16].

B. Ablations and Explainability

Future ablation studies should evaluate the contributions of organ priors, blacklist masking, and SUVmax-guided refinement to overall performance. Explainable AI (XAI) methods such as Grad-CAM and attention maps could provide visual interpretability, improve clinician trust and facilitate clinical adoption [19], [27].

C. Future Directions

The goal of this study is to address the difficulties in identifying malignant lung nodules promptly, before they progress to advanced stages. By using CT scans as input data, we propose a refined neural network classification framework to detect and categorize lung nodules with high precision. The overarching objective is to enhance the accuracy and efficiency of diagnostic workflows, enabling timely intervention and therapy for at-risk patients. In the future, further enhancements such as multimodal integration, active learning, and largescale external validation can advance clinical reliability and regulatory acceptance.

IX. CONCLUSION

This study presents an AI-powered PET-CT framework for automated lung lesion detection, segmentation, and TLG quantification, demonstrating high lesion-level sensitivity and excellent correlation with manual tumor burden assessment. By leveraging convolutional neural networks optimized for multichannel PET-CT data and incorporating refinement strategies such as SUVmax-guided watershed and blacklist masking, the system achieved reliable performance while reducing false positives near high-uptake non-lung organs. The strong agreement between AI-derived and manual TLG underscores its clinical applicability for prognosis, triage, and workflow optimization [23].

Our CNN-based classification model further achieved a test accuracy of 97.66% on CT scans, outperforming traditional CAD systems and supporting accurate disease prediction. This dual framework combining lesion segmentation with automated biomarker quantification offers a scalable solution to streamline radiologist workloads, reduce inter-observer variability, and support same-day multidisciplinary decisions.

Despite promising results, limitations remain, including reliance on a single-institution cohort and the lack of prospective, multi-center validation. Future work should prioritize dataset expansion, explainable AI integration, and federated learning for privacy-preserving generalization. With rigorous validation and regulatory alignment, AI-driven diagnostic systems hold the potential to transform lung cancer care through facilitating early detection, individualized treatment strategies, and enhanced patient outcomes.

REFERENCES

[1] "Multiple disease prediction using machine learning algorithms," Materials Today: Proceedings, vol. 80, pp. 3682–3685, 2023.

[2] C. Kaur, M. S. Kumar, A. Anjum, M. B. Binda, M. R. Mallu, and M. S. A. Ansari, "Chronic kidney disease prediction using machine learning," Journal of Advances in Information Technology, vol. 14, no. 2, pp. 384–391, 2023.

[3] N. Chandrasekhar and S. Peddakrishna, "Enhancing heart disease prediction accuracy through machine learning techniques and optimization," Processes, 2023.

[4] L. Pan, W. Sun, W. Wan, Q. Zeng, and J. Xu, "Research progress of diabetic disease prediction model in deep learning," Journal of Theory and Practice of Engineering Science, vol. 3, no. 12, pp. 15–21, 2023.

[5] K. Ramudu, "Machine learning and artificial intelligence in disease prediction: Applications, challenges, limitations, case studies, and future directions," in Contemporary Applications of Data Fusion for Advanced Healthcare Informatics, IGI Global, pp. 297–318, 2023.

[6] A. Khan, M. Q. Moiz, D. Kassim, and T. Tawiah, "A novel study on machine learning algorithm-based cardiovascular disease prediction," Health and Social Care in the Community, pp. 1–10, 2023.

[7] M. P. Behera, A. Sarangi, D. Mishra, S. K. Sarangi, "A hybrid machine learning algorithm for heart and liver disease prediction using modified particle swarm optimization with support vector machine," Procedia Computer Science, vol. 218, pp. 818–827, 2023.

[8] A. F. Farjana, T. L. Tabassum, P. P. Pandit, M. C. Das, M. H. Fariha, and Md. H. Hossen, "Predicting chronic kidney disease using machine learning algorithms," in IEEE 13th Annual Computing and Communication Workshop and Conference (CCWC), pp. 1267–1271, 2023.

[9] H. Khalid, A. Khan, M. Zahid Khan, G. Mehmood, and M. Shuaib Qureshi, "Machine learning hybrid model for the prediction of chronic kidney disease," Computational Intelligence and Neuroscience, 2023.

[10] C. Kulkarni, A. Quraishi, M. Raparthi, "Hybrid disease prediction approach leveraging digital twin and metaverse technologies for health consumer," BMC Medical Informatics and Decision Making, 2024.

[11] J. Mistry, A. Ganesh, R. Ramakrishnan, and J. Logeshwaran, "IoT based congenital heart disease prediction system to amplify the authentication and data security using cloud computing," European Chemical Bulletin, pp. 7201–7213, 2023.

[12] Z. K. Alkayyali, S. Anuar Bin Idris, and S. S. Abu-Naser, "A systematic literature review of deep and machine learning algorithms in cardiovascular diseases diagnosis," Journal of Theoretical and Applied Information Technology, pp. 1353–1365, 2023.

[13] P. Dileep, K. N. Rao, P. Bodapati, S. Gokuruboyina, R. Peddi, A. Grover, and A. Sheetal, "An automatic heart disease prediction using clusterbased bi-directional LSTM (C-Bi-LSTM) algorithm," Neural Computing and Applications, pp. 7253–7266, 2023.

[14] M. J. Page et al., "The PRISMA 2020 statement: an updated guideline for reporting systematic reviews," BMJ, 2021.

[15] O. Ronneberger, P. Fischer, and T. Brox, "U-Net: Convolutional Networks for Biomedical Image Segmentation," in MICCAI, 2015.

[16] K. He et al., "Deep Residual Learning for Image Recognition," in CVPR, 2016.

[17] S. Armato et al., "The Lung Image Database Consortium (LIDC) and Image Database Resource Initiative (IDRI)," Med. Phys., 2011.

[18] J. M. Bland and D. G. Altman, "Statistical methods for assessing agreement," The Lancet, 1986.

[19] F. Doshi-Velez and B. Kim, “Towards a Rigorous Science of Interpretable ML,” 2017.
[20] H. M. Hudson and R. S. Larkin, “Accelerated image reconstruction using ordered subsets of projection data,” IEEE TMI, 1994.
[21] D. P. Kingma and J. Ba, “Adam: A Method for Stochastic Optimization,” 2015.
[22] G. Jocher et al., “YOLOv8,” 2023. [Online]. Available: https://docs. ultralytics.com
[23] A. Hatt et al., “Reproducibility of TLG and MTV in FDG PET for oncology,” Eur. J. Nucl. Med. Mol. Imaging, 2013.
[24] International Agency for Research on Cancer (IARC) / World Health Organization. “GLOBOCAN 2020: Estimated cancer incidence, mortality and prevalence worldwide in 2020.” Available: https://gco.iarc.fr/ (accessed 2024).
[25] National Lung Screening Trial Research Team, “Reduced lung-cancer mortality with low-dose computed tomographic screening,” New England Journal of Medicine, vol. 365, no. 5, pp. 395–409, 2011.
[26] B. Sheller, G. Edwards, G. Reina, J. Martin, and S. Bakas, “Federated learning in medicine: facilitating multi-institutional collaborations without sharing patient data,” Scientific Reports, vol. 10, no. 1, pp. 12598, 2020.
[27] S. Lundberg and S. Lee, “A unified approach to interpreting model predictions,” in NeurIPS, 2017.
[28] H. Ardila et al., “End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography,” Nature Medicine, vol. 25, no. 6, pp. 954–961, 2019.